UTHR,TXMD,DOC Stock Price and Quote

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: AMGN PFE LLY MRK REGN JNJ BMY VRTX GILD BIIB

| Held by: IJH VTI VB VBR VXF XMHQ MDY IBB IJK SPMD

Index	-	P/E	19.22	EPS (ttm)	27.90	Insider Own	3.41%	Shs Outstand	43.64M	Perf Week	12.12%
Market Cap	23.50B	Forward P/E	16.14	EPS next Y	33.23	Insider Trans	-43.84%	Shs Float	42.33M	Perf Month	12.67%
Enterprise Value	20.58B	PEG	1.40	EPS next Q	7.01	Inst Own	95.51%	Short Float	4.09%	Perf Quarter	10.57%
Income	1.33B	P/S	7.38	EPS this Y	5.57%	Inst Trans	-0.39%	Short Ratio	3.88	Perf Half Y	32.43%
Sales	3.18B	P/B	3.30	EPS next Y	12.97%	ROA	17.33%	Short Interest	1.73M	Perf YTD	10.03%
Book/sh	162.60	P/C	8.05	EPS next 5Y	11.55%	ROE	19.71%	52W High	548.12 -2.19%	Perf Year	75.55%
Cash/sh	66.63	P/FCF	22.58	EPS past 3/5Y	22.94% 19.27%	ROIC	18.81%	52W Low	266.98 100.81%	Perf 3Y	138.57%
Dividend Est.	-	EV/EBITDA	12.85	Sales past 3/5Y	18.02% 16.50%	Gross Margin	87.92%	Volatility	3.75% 3.73%	Perf 5Y	236.13%
Dividend TTM	-	EV/Sales	6.47	EPS Y/Y TTM	14.09%	Oper. Margin	47.63%	ATR (14)	18.22	Perf 10Y	330.13%
Dividend Ex-Date	-	Quick Ratio	6.28	Sales Y/Y TTM	10.61%	Profit Margin	41.94%	RSI (14)	61.92	Recom	1.56
Dividend Gr. 3/5Y	- -	Current Ratio	6.60	EPS Q/Q	24.49%	SMA20	7.00%	Beta	0.83	Target Price	598.82
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	7.38%	SMA50	9.95%	Rel Volume	1.18	Prev Close	532.82
Employees	1400	LT Debt/Eq	0.00	Earnings	Feb 25 BMO	SMA200	30.56%	Avg Volume	446.64K	Price	536.12
IPO	Jun 17, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.00% -2.81%	Trades		Volume	544,885	Change	0.62%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Underweight	$414
Sep-26-25	Initiated	RBC Capital Mkts	Outperform	$569
Jun-02-25	Initiated	Cantor Fitzgerald	Overweight	$405
Apr-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-21-25	Upgrade	BofA Securities	Underperform → Neutral	$314
Jul-11-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$310 → $321
Feb-12-24	Upgrade	Goldman	Sell → Neutral	$213 → $215
Feb-05-24	Initiated	Leerink Partners	Outperform	$330
Dec-08-23	Initiated	Wells Fargo	Overweight	$309
Dec-06-22	Initiated	UBS	Buy	$320
Dec-05-22	Initiated	Goldman	Sell	$230
Oct-11-22	Initiated	Morgan Stanley	Overweight	$288
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform	$263
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy	$205
Apr-26-21	Resumed	Credit Suisse	Outperform	$196
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy	$125 → $195
Sep-14-20	Resumed	JP Morgan	Overweight	$142
Jun-25-20	Reiterated	H.C. Wainwright	Neutral	$85 → $125

Show Previous Ratings

Mar-11-26 06:14PM	United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine (Business Wire)
Mar-10-26 06:09AM	United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains? (Zacks)
Mar-09-26 12:49PM	Crude Falls Below $100 As Trump Mulls Emergency Reserve Release: What's Moving Markets Monday? (Benzinga) +10.67%
07:00AM	United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program (Business Wire)
Mar-04-26 01:35PM	Xenon Pharmaceuticals Stock Sees RS Rating Rise To 77 (Investor's Business Daily)
07:00AM	Loading…
Mar-03-26 07:00AM	United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference (Business Wire)
Mar-02-26 10:32AM	United Therapeutics' Trial Shows 55% Drop in Lung Disease Worsening (Benzinga)
06:30AM	United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy (Business Wire)
Mar-01-26 10:04AM	H.C. Wainwright Raises United Therapeutics (UTHR) Target to $600 (Insider Monkey)
Feb-27-26 05:29AM	Zoetis Stock: Is ZTS Underperforming the Healthcare Sector? (Barchart)
Feb-26-26 05:03PM	MannKind Q4 Earnings Call Highlights (MarketBeat) -5.89%
04:02PM	Stocks Showing Market Leadership: United Therapeutics Earns 91 RS Rating (Investor's Business Daily)
12:25PM	Why United Therapeutics (UTHR) Shares Are Sliding Today (StockStory)
09:02AM	UTHR Tops Q4 Earnings Estimates, Shares Surge 13% on Strong Guidance (Zacks)
07:42AM	Stock Market News for Feb 26, 2026 (Zacks)
04:32AM	Loading…
04:32AM	United Therapeutics Q4 Earnings Call Highlights (MarketBeat)
Feb-25-26 04:33PM	United Therapeutics Corporation Q4 2025 Earnings Call Summary (Moby) +13.03%
04:02PM	United Therapeutics Corp (UTHR) Q4 2025 Earnings Call Highlights: Record Revenue and Promising ... (GuruFocus.com)
12:30PM	Compared to Estimates, United Therapeutics (UTHR) Q4 Earnings: A Look at Key Metrics (Zacks)
12:15PM	United Therapeutics (UTHR) Surpasses Q4 Earnings Estimates (Zacks)
06:47AM	United Therapeutics (NASDAQ:UTHR) Misses Q4 CY2025 Revenue Estimates (StockStory)
06:45AM	United Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-23-26 10:22PM	United Therapeutics (UTHR) Q4 Earnings Report Preview: What To Look For (StockStory)
11:40AM	USNA or UTHR: Which Is the Better Value Stock Right Now? (Zacks)
07:00AM	United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference (Business Wire)
Feb-20-26 09:15AM	Unveiling United Therapeutics (UTHR) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Feb-17-26 05:25PM	USANA Health Sciences (USNA) Q4 Earnings and Revenues Beat Estimates (Zacks)
Feb-11-26 07:00AM	United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026 (Business Wire)
Feb-06-26 11:04AM	Merck's Subdued 2026 Outlook: What it Means After Q4 Results? (Zacks)
10:32PM	Loading…
Jan-29-26 10:32PM	A Look Back at Therapeutics Stocks' Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack (StockStory)
Jan-28-26 10:15AM	Merck's Non-Oncology Drugs Q4 Performance: What to Expect (Zacks)
Jan-27-26 10:33PM	Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR) (StockStory)
Jan-26-26 08:55AM	United Therapeutics Reports Early Success For External Liver Support In Acute Failure (Benzinga)
07:00AM	United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP in Patients with Acute Liver Failure (Business Wire)
Jan-22-26 07:00AM	United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors (Business Wire)
Jan-19-26 05:17PM	United Therapeutics Corporation (UTHR): A Bull Case Theory (Insider Monkey)
Jan-16-26 09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
Jan-15-26 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
Jan-13-26 10:39AM	6 stocks and ETFs that these unsung market heroes see outperforming in 2026 (MarketWatch)
Jan-12-26 03:57PM	6 stocks and ETFs that these unsung market heroes see outperforming in 2026 (MarketWatch)
08:55AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
Jan-08-26 11:40AM	UTHR or MDGL: Which Is the Better Value Stock Right Now? (Zacks)
Jan-07-26 11:40AM	UTHR vs. ZTS: Which Stock Is the Better Value Option? (Zacks)
Jan-05-26 07:00AM	United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-31-25 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks)
Dec-30-25 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
Dec-15-25 09:50AM	MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAH (Zacks)
Dec-11-25 09:50AM	Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock (Zacks)
Dec-10-25 11:30AM	Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report? (Zacks)
09:40AM	Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term (Zacks)
Dec-09-25 12:26PM	This Gold Stock Hits A High, With Miner Poised For Huge Swing To Profit (Investor's Business Daily)
09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
Dec-05-25 11:30AM	Catalyst (CPRX) Up 10% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-04-25 11:30AM	Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue? (Zacks)
11:20AM	Can Merck's New Products Aid Growth as Keytruda LOE Test Looms? (Zacks)
Dec-03-25 07:19AM	Flurry of Bullish Inflows Sends United Therapeutics Higher (FX Empire)
Nov-21-25 12:04PM	United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base (Investor's Business Daily)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-20-25 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks)
Nov-19-25 10:52AM	Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study (Zacks)
Nov-12-25 09:50AM	Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-09-25 11:02PM	3 Reasons Investors Love United Therapeutics (UTHR) (StockStory)
Nov-05-25 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
12:35AM	The 5 Most Interesting Analyst Questions From United Therapeutics's Q3 Earnings Call (StockStory)
Nov-04-25 09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
07:00AM	United Therapeutics Corporation to Present at Upcoming Investor Conferences (Business Wire)
Nov-03-25 07:00AM	United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease (Business Wire)
Oct-30-25 03:48PM	United Therapeutics Corp (UTHR) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
11:40AM	MKKGY vs. UTHR: Which Stock Is the Better Value Option? (Zacks)
01:38AM	UTHR Q3 Deep Dive: Clinical Pipeline Advances and High-Dose Product Launches Drive Outlook (StockStory)
Oct-29-25 04:14PM	United Therapeutics Rockets 10% On Growing Enthusiasm For Its Top Drug (Investor's Business Daily) +9.63%
01:11PM	Why Is United Therapeutics (UTHR) Stock Soaring Today (StockStory)
11:24AM	United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
09:55AM	The Mixed Results For United Therapeutics' Bread-And-Butter Drug (Investor's Business Daily)
09:30AM	Compared to Estimates, United Therapeutics (UTHR) Q3 Earnings: A Look at Key Metrics (Zacks)
08:51AM	United Therapeutics Dips As Bread-And-Butter Drug Comes Up Short (Investor's Business Daily)
07:40AM	United Therapeutics (UTHR) Beats Q3 Earnings Estimates (Zacks)
06:48AM	United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q3 Earnings (StockStory)
06:43AM	United Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results (Business Wire)
Oct-27-25 11:17PM	United Therapeutics (UTHR) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-24-25 10:05AM	Merck's Non-Oncology Drugs Q3 Performance: What to Expect (Zacks)
Oct-23-25 10:00AM	Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-22-25 10:00AM	United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Oct-16-25 03:51PM	Jefferies Reiterates Buy Rating on United Therapeutics (UTHR) Amid Patent Case (Insider Monkey)
Oct-15-25 07:00AM	United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025 (Business Wire)
Oct-13-25 07:00AM	United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting (Business Wire)
Oct-01-25 10:40AM	Is IPF the Next Big Market Opportunity for United Therapeutics? (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Sep-30-25 04:38PM	Top Stock Reports for NextEra Energy, U.S. Bancorp and Air Products & Chemicals (Zacks)
Sep-26-25 09:46AM	CarMax downgraded, Kenvue upgraded: Wall Street's top analyst calls (The Fly)
Sep-19-25 11:53AM	Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE? (Zacks)
07:00AM	United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso in Idiopathic Pulmonary Fibrosis (Business Wire)
12:46AM	1 Momentum Stock to Target This Week and 2 We Brush Off (StockStory)
12:03AM	3 Big Reasons to Love United Therapeutics (UTHR) (StockStory)
Sep-16-25 07:00AM	United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum (Business Wire)
Sep-12-25 07:00AM	United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress (Business Wire)
Sep-11-25 11:30AM	Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue? (Zacks)

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROTHBLATT MARTINE A	Chairperson & CEO	Mar 11 '26	Option Exercise	146.03	9,500	1,387,285	9,630	Mar 11 07:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Mar 11 '26	Sale	539.54	9,500	5,125,647	130	Mar 11 07:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Mar 10 '26	Option Exercise	146.03	9,500	1,387,285	9,630	Mar 11 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Mar 10 '26	Sale	539.71	9,500	5,127,273	130	Mar 11 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Mar 09 '26	Option Exercise	146.03	9,500	1,387,285	9,630	Mar 10 04:34 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Mar 09 '26	Sale	518.03	9,500	4,921,275	130	Mar 10 04:34 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Mar 06 '26	Option Exercise	146.03	9,500	1,387,285	9,630	Mar 10 04:33 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Mar 06 '26	Sale	477.67	9,500	4,537,853	130	Mar 10 04:33 PM
Olian Judy D.	Director	Mar 06 '26	Sale	510.00	200	102,000	4,645	Mar 09 04:36 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Mar 05 '26	Option Exercise	146.03	9,500	1,387,285	9,630	Mar 09 04:36 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Mar 05 '26	Sale	484.55	9,500	4,603,232	130	Mar 09 04:36 PM
JUDY OLIAN	Director	Mar 09 '26	Proposed Sale	510.00	200	102,000		Mar 09 04:04 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Mar 05 '26	Option Exercise	146.03	8,300	1,212,049	45,144	Mar 05 04:37 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Mar 05 '26	Sale	483.16	8,300	4,010,187	36,844	Mar 05 04:37 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Mar 04 '26	Sale	489.91	9,500	4,654,129	130	Mar 05 04:36 PM
KURZWEIL RAY	Director	Mar 04 '26	Option Exercise	101.80	4,910	499,838	17,580	Mar 05 04:36 PM
KURZWEIL RAY	Director	Mar 04 '26	Sale	489.02	4,910	2,401,088	12,670	Mar 05 04:36 PM
Thompson Tommy G	Director	Mar 04 '26	Option Exercise	101.80	2,000	203,600	10,480	Mar 05 04:35 PM
Thompson Tommy G	Director	Mar 04 '26	Sale	489.42	2,000	978,839	8,480	Mar 05 04:35 PM
CAUSEY CHRISTOPHER	Director	Mar 04 '26	Option Exercise	119.76	20	2,395	4,210	Mar 05 04:34 PM
CAUSEY CHRISTOPHER	Director	Mar 04 '26	Sale	490.17	20	9,803	4,190	Mar 05 04:34 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Mar 03 '26	Option Exercise	146.03	9,500	1,387,285	9,630	Mar 05 04:33 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Mar 03 '26	Sale	499.42	9,500	4,744,467	130	Mar 05 04:33 PM
PAUL MAHON	Officer	Mar 05 '26	Proposed Sale	483.16	8,300	4,010,187		Mar 05 04:03 PM
CHRISTOPHER CAUSEY	Director	Mar 04 '26	Proposed Sale	490.17	20	9,803		Mar 04 04:25 PM
TOMMY THOMPSON	Director	Mar 04 '26	Proposed Sale	489.42	2,000	978,839		Mar 04 04:08 PM
RAYMOND KURZWEIL	Director	Mar 04 '26	Proposed Sale	489.02	4,910	2,401,088		Mar 04 04:07 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Mar 02 '26	Option Exercise	146.03	9,500	1,387,285	9,630	Mar 03 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Mar 02 '26	Sale	515.37	9,500	4,896,019	130	Mar 03 04:31 PM
JAN MALCOLM	Director	Mar 03 '26	Proposed Sale	509.20	50	25,460		Mar 03 04:23 PM
MARTINE ROTHBLATT	Director	Mar 02 '26	Proposed Sale	503.90	209,000	105,315,100		Mar 02 04:43 PM
Olian Judy D.	Director	Feb 27 '26	Sale	509.55	200	101,910	4,845	Mar 02 04:30 PM
JUDY OLIAN	Director	Mar 02 '26	Proposed Sale	509.55	200	101,910		Mar 02 04:16 PM
CHRISTOPHER CAUSEY	Director	Feb 25 '26	Proposed Sale	520.00	1,000	520,000		Feb 25 04:42 PM
CAUSEY CHRISTOPHER	Director	Feb 25 '26	Option Exercise	119.76	1,000	119,760	5,190	Feb 25 04:31 PM
CAUSEY CHRISTOPHER	Director	Feb 25 '26	Sale	520.00	1,000	520,000	4,190	Feb 25 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 23 '26	Option Exercise	127.68	14,440	1,843,642	9,375	Feb 24 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 23 '26	Sale	472.13	14,440	6,817,499	0	Feb 24 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Feb 19 '26	Option Exercise	146.03	8,300	1,212,049	45,081	Feb 19 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Feb 19 '26	Sale	476.34	8,300	3,953,588	36,781	Feb 19 04:31 PM
PAUL MAHON	Officer	Feb 19 '26	Proposed Sale	476.34	8,300	3,953,588		Feb 19 04:02 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 17 '26	Option Exercise	127.65	22,500	2,872,226	14,625	Feb 18 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 17 '26	Sale	480.75	22,500	10,816,956	0	Feb 18 04:31 PM
MALCOLM JAN	Director	Feb 17 '26	Sale	474.68	50	23,734	220	Feb 17 04:32 PM
JAN MALCOLM	Director	Feb 17 '26	Proposed Sale	474.68	50	23,734		Feb 17 04:19 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 09 '26	Option Exercise	127.65	22,500	2,872,226	14,625	Feb 10 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 09 '26	Sale	474.65	22,500	10,679,686	0	Feb 10 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Feb 05 '26	Option Exercise	146.03	8,300	1,212,049	45,081	Feb 05 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Feb 05 '26	Sale	483.25	8,300	4,010,940	36,781	Feb 05 04:31 PM
PAUL MAHON	Officer	Feb 05 '26	Proposed Sale	483.25	8,300	4,010,939		Feb 05 04:03 PM
MALCOLM JAN	Director	Feb 03 '26	Sale	474.23	50	23,712	270	Feb 03 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 02 '26	Option Exercise	127.65	22,500	2,872,226	14,625	Feb 03 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 02 '26	Sale	470.95	22,500	10,596,429	0	Feb 03 04:31 PM
JAN MALCOLM	Director	Feb 03 '26	Proposed Sale	474.23	50	23,712		Feb 03 04:03 PM
Michael Benkowitz	Officer	Feb 02 '26	Proposed Sale	469.49	90,000	42,254,100		Feb 02 04:29 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 26 '26	Option Exercise	127.65	22,500	2,872,226	14,625	Jan 28 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 20 '26	Option Exercise	146.03	7,875	1,149,986	7,875	Jan 28 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 26 '26	Sale	471.91	22,500	10,617,932	0	Jan 28 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 20 '26	Sale	464.66	7,875	3,659,182	0	Jan 28 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 20 '26	Sale	464.66	14,625	6,795,627	0	Jan 28 04:30 PM
MALCOLM JAN	Director	Jan 16 '26	Sale	460.98	50	23,049	320	Jan 20 04:30 PM
JAN MALCOLM	Director	Jan 20 '26	Proposed Sale	460.98	50	23,049		Jan 20 04:02 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 15 '26	Option Exercise	146.03	8,300	1,212,049	45,081	Jan 15 04:32 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 15 '26	Sale	469.89	8,300	3,900,122	36,781	Jan 15 04:32 PM
PAUL MAHON	Officer	Jan 15 '26	Proposed Sale	469.89	8,300	3,900,122		Jan 15 04:06 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 12 '26	Option Exercise	127.65	22,500	2,872,226	14,625	Jan 13 05:10 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 12 '26	Sale	479.51	22,500	10,788,876	0	Jan 13 05:10 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 05 '26	Option Exercise	117.76	14,625	1,722,240	14,625	Jan 07 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 05 '26	Sale	487.38	14,625	7,127,877	0	Jan 07 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 05 '26	Option Exercise	146.03	7,875	1,149,986	7,875	Jan 07 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 05 '26	Sale	487.38	7,875	3,838,085	0	Jan 07 04:30 PM
CAUSEY CHRISTOPHER	Director	Jan 06 '26	Option Exercise	119.76	1,000	119,760	5,190	Jan 06 04:31 PM
CAUSEY CHRISTOPHER	Director	Jan 06 '26	Sale	510.00	1,000	510,000	4,190	Jan 06 04:31 PM
MALCOLM JAN	Director	Jan 05 '26	Sale	495.01	50	24,750	370	Jan 06 04:31 PM
CHRISTOPHER CAUSEY	Director	Jan 06 '26	Proposed Sale	510.00	1,000	510,000		Jan 06 04:07 PM
JAN MALCOLM	Director	Jan 06 '26	Proposed Sale	495.01	50	24,750		Jan 06 04:06 PM
CAUSEY CHRISTOPHER	Director	Jan 02 '26	Option Exercise	119.76	1,000	119,760	5,190	Jan 05 04:59 PM
CAUSEY CHRISTOPHER	Director	Jan 02 '26	Sale	500.01	1,000	500,015	4,190	Jan 05 04:59 PM
Michael Benkowitz	Officer	Jan 05 '26	Proposed Sale	496.72	90,000	44,704,800		Jan 05 04:39 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 02 '26	Option Exercise	146.03	8,300	1,212,049	45,081	Jan 02 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 02 '26	Sale	485.43	8,300	4,029,076	36,781	Jan 02 04:30 PM
CHRISTOPHER CAUSEY	Director	Jan 02 '26	Proposed Sale	500.01	1,000	500,015		Jan 02 04:22 PM
PAUL MAHON	Officer	Jan 02 '26	Proposed Sale	485.43	8,300	4,029,076		Jan 02 04:12 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 29 '25	Option Exercise	146.03	7,875	1,149,986	7,875	Dec 30 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 29 '25	Sale	502.79	22,500	11,312,710	0	Dec 30 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 24 '25	Option Exercise	146.03	11,000	1,606,330	47,781	Dec 29 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 24 '25	Sale	513.18	11,000	5,644,954	36,781	Dec 29 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 22 '25	Option Exercise	146.03	7,875	1,149,986	7,875	Dec 29 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 22 '25	Sale	514.35	22,500	11,572,963	0	Dec 29 04:30 PM
PAUL MAHON	Officer	Dec 24 '25	Proposed Sale	513.18	11,000	5,644,954		Dec 29 09:37 AM
MALCOLM JAN	Director	Dec 23 '25	Sale	512.12	50	25,606	420	Dec 23 04:33 PM
SULLIVAN LOUIS W	Director	Dec 22 '25	Option Exercise	204.93	5,950	1,219,339	5,950	Dec 23 04:33 PM
SULLIVAN LOUIS W	Director	Dec 22 '25	Sale	512.13	5,950	3,047,201	0	Dec 23 04:33 PM
LOUIS WADE SULLIVAN REVOCABLE	Affiliate	Dec 22 '25	Proposed Sale	512.13	5,950	3,047,200		Dec 22 05:13 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 19 '25	Proposed Sale	507.07	2,000	1,014,143		Dec 19 05:39 PM
Thompson Tommy G	Director	Dec 18 '25	Option Exercise	101.80	910	92,638	9,390	Dec 19 04:31 PM
Thompson Tommy G	Director	Dec 18 '25	Sale	500.59	910	455,533	8,480	Dec 19 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 17 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 19 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 18 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 19 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 19 '25	Option Exercise	120.26	2,000	240,520	2,130	Dec 19 04:30 PM

TXMD TherapeuticsMD Inc daily Stock Chart

Peers: VERU SNDX ARCT TGTX ONCY ATNM VRCA IBRX HRTG GNPX

| Held by: VTI VXF

Index	-	P/E	83.14	EPS (ttm)	0.03	Insider Own	1.62%	Shs Outstand	11.57M	Perf Week	-3.56%
Market Cap	25.12M	Forward P/E	-	EPS next Y	-	Insider Trans	4.69%	Shs Float	11.39M	Perf Month	-10.70%
Enterprise Value	24.48M	PEG	-	EPS next Q	-	Inst Own	29.25%	Short Float	0.40%	Perf Quarter	15.43%
Income	0.30M	P/S	8.97	EPS this Y	-	Inst Trans	0.79%	Short Ratio	0.55	Perf Half Y	95.50%
Sales	2.80M	P/B	0.92	EPS next Y	-	ROA	0.19%	Short Interest	0.05M	Perf YTD	33.13%
Book/sh	2.37	P/C	3.53	EPS next 5Y	-	ROE	0.27%	52W High	2.95 -26.44%	Perf Year	194.56%
Cash/sh	0.62	P/FCF	12.14	EPS past 3/5Y	79.41% 64.95%	ROIC	0.92%	52W Low	0.72 201.39%	Perf 3Y	-43.78%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-11.87% -48.72%	Gross Margin	86.16%	Volatility	3.88% 5.26%	Perf 5Y	-97.27%
Dividend TTM	-	EV/Sales	8.74	EPS Y/Y TTM	109.08%	Oper. Margin	-93.71%	ATR (14)	0.14	Perf 10Y	-99.36%
Dividend Ex-Date	-	Quick Ratio	2.46	Sales Y/Y TTM	75.19%	Profit Margin	10.80%	RSI (14)	43.16	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.46	EPS Q/Q	124.81%	SMA20	-4.30%	Beta	0.53	Target Price	5.00
Payout	-	Debt/Eq	0.24	Sales Q/Q	43.33%	SMA50	-3.55%	Rel Volume	0.26	Prev Close	2.28
Employees	1	LT Debt/Eq	0.20	Earnings	Nov 12 AMC	SMA200	43.50%	Avg Volume	81.93K	Price	2.17
IPO	Jan 03, 2002	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	21,255	Change	-4.82%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-07-20	Downgrade	Jefferies	Hold → Underperform
May-19-20	Downgrade	JP Morgan	Overweight → Neutral
Dec-02-19	Initiated	Guggenheim	Buy
Oct-17-19	Initiated	H.C. Wainwright	Buy	$7
Apr-30-19	Resumed	Noble Capital Markets	Outperform	$13
Jun-15-18	Initiated	JP Morgan	Overweight	$11
Sep-08-17	Initiated	Morgan Stanley	Equal-Weight	$6
Jul-11-17	Upgrade	Oppenheimer	Perform → Outperform
May-09-17	Downgrade	Oppenheimer	Outperform → Perform
Nov-22-16	Resumed	Jefferies	Buy	$18
Nov-22-16	Initiated	Oppenheimer	Outperform
Nov-07-16	Resumed	Guggenheim	Buy
Apr-04-16	Initiated	Goldman	Buy	$10
Dec-08-15	Reiterated	Stifel	Buy	$10 → $14
Dec-08-15	Reiterated	Jefferies	Buy	$15 → $18
Sep-21-15	Reiterated	Jefferies	Buy	$7 → $15
Jun-09-15	Initiated	Guggenheim	Buy
Jul-08-14	Initiated	FBR Capital	Outperform	$34
Apr-17-14	Reiterated	Noble Financial	Buy	$9 → $13
Jan-28-14	Reiterated	Noble Financial	Buy	$7.25 → $9

Show Previous Ratings

Nov-12-25 06:04PM	TherapeuticsMD: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces Third Quarter 2025 Financial Results (Business Wire)
Aug-12-25 04:47PM	TherapeuticsMD: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces Second Quarter 2025 Financial Results (Business Wire)
May-13-25 05:02PM	TherapeuticsMD: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	TherapeuticsMD Announces First Quarter 2025 Financial Results (Business Wire)
Mar-27-25 04:05PM	TherapeuticsMD Announces Full Year 2024 Financial Results (Business Wire) -6.48%
Nov-12-24 04:32PM	TherapeuticsMD: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces Third Quarter 2024 Financial Results (Business Wire)
Aug-12-24 05:26PM	TherapeuticsMD: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces Second Quarter 2024 Financial Results (Business Wire)
Jun-28-24 11:52AM	TXMD Stock Earnings: TherapeuticsMD Reported Results for Q4 2023 (InvestorPlace) -7.47%
May-10-24 08:53PM	TXMD Stock Earnings: TherapeuticsMD Reported Results for Q1 2024 (InvestorPlace)
04:43PM	TherapeuticsMD: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces First Quarter 2024 Financial Results (Business Wire)
04:00PM	Loading…
Mar-29-24 04:00PM	TherapeuticsMD Announces Full Year 2023 Financial Results (Business Wire)
Mar-12-24 11:40AM	25 Countries With Highest Abortion Rates (Insider Monkey) +6.95%
Jan-30-24 11:20PM	12 Best Prenatal Vitamins For Pregnant Women (Insider Monkey)
Nov-15-23 05:08AM	TherapeuticsMD: Q3 Earnings Snapshot (Associated Press Finance) +17.41%
Nov-14-23 04:05PM	TherapeuticsMD Announces Third Quarter 2023 Financial Results (Business Wire)
Aug-14-23 07:52AM	TherapeuticsMD: Q2 Earnings Snapshot (Associated Press Finance)
06:50AM	TherapeuticsMD Announces Second Quarter 2023 Financial Results (Business Wire)
May-15-23 05:56PM	TherapeuticsMD: Q1 Earnings Snapshot (AP Finance)
04:05PM	TherapeuticsMD Announces First Quarter 2023 Financial Results (Business Wire)
Apr-14-23 12:00PM	All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy (Zacks)
Apr-07-23 04:01PM	TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition (Business Wire)
Jan-03-23 06:50AM	TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma (Business Wire) +11.81%
Dec-08-22 10:42AM	Boca pharma company will cut 212 employees after failed buyout (American City Business Journals)
Dec-04-22 06:00PM	TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma (Business Wire)
Nov-14-22 07:55PM	TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.45% -8.20%
04:05PM	Loading…
04:05PM	TherapeuticsMD Announces Third Quarter 2022 Financial Results (Business Wire)
Oct-31-22 06:50AM	TherapeuticsMD Announces Additional $7 Million Private Placement (Business Wire) +6.21%
Oct-03-22 01:45PM	TherapeuticsMD receives $7M investment after merger plans unravel (American City Business Journals) -7.53%
06:50AM	TherapeuticsMD Announces $7 Million Private Placement (Business Wire)
Sep-12-22 06:50AM	TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers (Business Wire) +5.55%
Aug-15-22 01:00PM	TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Call Transcript (Motley Fool)
08:05AM	TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:50AM	TherapeuticsMD Announces Second Quarter 2022 Financial Results (Business Wire)
Aug-08-22 06:50AM	TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022 (Business Wire)
Aug-01-22 01:00PM	Pharma firm receives $15M investment after canceled merger (American City Business Journals) +36.60%
06:50AM	TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital (Business Wire)
Jul-15-22 01:34PM	HC Wainwright Rating & Price Target On TherapeuticsMD Under Review On 'Unclear Path' (Benzinga) +12.50%
Jul-13-22 09:48AM	Why TherapeuticsMD Shares Are Sinking Today? (Benzinga) -35.55%
08:25AM	TherapeuticsMD's stock falls 41% after tender offer expires (MarketWatch)
06:50AM	TherapeuticsMD Announces Expiration of Tender Offer (Business Wire)
Jul-06-22 06:09AM	EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer (PR Newswire)
Jun-06-22 04:05PM	EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD (PR Newswire)
May-31-22 06:00AM	TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD (Business Wire) +364.02%
May-20-22 10:52AM	Why TherapeuticsMD Shares Are Trading Higher Today (Benzinga) +36.56%
09:43AM	TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA® (Business Wire)
May-16-22 08:00PM	TherapeuticsMD, Inc. (TXMD) Q1 2022 Earnings Call Transcript (Motley Fool) -14.01%
05:45PM	TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	TherapeuticsMD Announces First Quarter 2022 Financial Results (Business Wire)
May-12-22 05:25PM	Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -13.87%
May-10-22 04:05PM	TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022 (Business Wire) -24.78%
Apr-14-22 04:15PM	TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million (Business Wire)
Mar-10-22 01:30PM	TherapeuticsMD, Inc. (TXMD) Q4 2021 Earnings Call Transcript (Motley Fool) -27.50%
08:05AM	TherapeuticsMD (TXMD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:50AM	TherapeuticsMD Announces Fourth Quarter 2021 Financial Results (Business Wire)
Mar-07-22 12:57PM	TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal (Benzinga) +43.05%
07:40AM	TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx (Business Wire)
Mar-01-22 04:30PM	TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022 (Business Wire) -5.69%
Feb-28-22 05:35PM	Nektar Therapeutics (NKTR) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +8.28%
Feb-24-22 09:05AM	Radius Health (RDUS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Jan-25-22 08:52AM	TherapeuticsMD, Inc. (NASDAQ:TXMD): Is Breakeven Near? (Simply Wall St.)
Jan-06-22 07:29AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Jan-04-22 06:20AM	FDA Approves TherapeuticsMD's Low Dose Bijuva (Benzinga) +11.18%
Dec-28-21 09:53AM	Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options (Zacks)
Dec-13-21 06:08AM	TherapeuticsMD's Birth Control Med Receives FDA Response Letter To Revise Manufacturing Testing Limits (Benzinga) -11.51%
Dec-10-21 04:30PM	U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA® (Business Wire)
Dec-08-21 06:50AM	TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) Allowing for a May 25, 2032 Generic Entry Date (Business Wire)
Nov-24-21 07:54AM	TherapeuticsMD (NASDAQ:TXMD) investors are sitting on a loss of 90% if they invested five years ago (Simply Wall St.)
Nov-22-21 10:40AM	Therapeuticsmd Insider Trades $580K In Company Stock (Benzinga)
Nov-12-21 03:00AM	TherapeuticsMD, Inc. (TXMD) Q3 2021 Earnings Call Transcript (Motley Fool)
Nov-11-21 06:50AM	TherapeuticsMD Announces Third Quarter 2021 Financial Results (Business Wire) -7.82%
06:45AM	TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh ODowd, as Chief Executive Officer (Business Wire)
Nov-04-21 03:01PM	TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-27-21 05:00PM	TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021 (Business Wire)
Oct-15-21 05:33PM	TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer (Business Wire)
Oct-05-21 01:28PM	What Type Of Shareholders Own The Most Number of TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares? (Simply Wall St.)
Oct-04-21 09:20AM	Where Do Hedge Funds Stand On TherapeuticsMD Inc (TXMD)? (Insider Monkey)
Sep-02-21 06:50AM	Therapeutics MD Is Urging Women to Take Pause During Menopause Awareness Month (Business Wire) +7.71%
Aug-23-21 06:50AM	TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector (Business Wire) +7.12%
Aug-19-21 08:01AM	5 Penny Stocks Insiders Are Buying (Benzinga) +5.53%
Aug-09-21 04:30PM	TherapeuticsMD Announces Appointment of Hugh ODowd as President (Business Wire)
Aug-04-21 08:05AM	TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.66%
06:50AM	TherapeuticsMD Announces Second Quarter 2021 Financial Results (Business Wire)
Jul-28-21 03:03PM	Will TherapeuticsMD (TXMD) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-26-21 06:50AM	TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021 (Business Wire)
Jul-06-21 11:49AM	10 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman (Insider Monkey)
Jun-29-21 08:58AM	Breakeven On The Horizon For TherapeuticsMD, Inc. (NASDAQ:TXMD) (Simply Wall St.)
May-25-21 06:50AM	TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA (Business Wire)
May-24-21 07:00AM	The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award (Business Wire)
May-07-21 01:31AM	TherapeuticsMD, Inc. (TXMD) Q1 2021 Earnings Call Transcript (Motley Fool)
May-06-21 10:56AM	TherapeuticsMD Shares Plunge On Declining Gross Margin, Total Prescription Volume (Benzinga) -13.28%
08:20AM	TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TherapeuticsMD Announces First Quarter 2021 Financial Results (Business Wire)
06:45AM	TherapeuticsMD, Inc. to Host Earnings Call (ACCESSWIRE)
May-03-21 07:00AM	TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting (Business Wire)
Apr-29-21 10:34AM	TherapeuticsMD's (NASDAQ:TXMD) Shareholders Are Down 85% On Their Shares (Simply Wall St.)

TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thompson Tommy G	Director	Dec 23 '25	Buy	1.67	8,400	14,031	23,179	Dec 29 04:23 PM
Thompson Tommy G	Director	Apr 14 '25	Buy	1.00	325	326	14,779	Apr 15 07:59 AM
Walker Marlan D	Chief Executive Officer	Apr 14 '25	Buy	1.00	490	489	73,639	Apr 15 07:59 AM
Walker Marlan D	Chief Executive Officer	Apr 10 '25	Buy	0.86	1,167	1,000	73,149	Apr 10 04:29 PM
Walker Marlan D	Chief Executive Officer	Apr 09 '25	Buy	0.87	1,136	994	71,982	Apr 10 04:29 PM

DOC Healthpeak Properties Inc daily Stock Chart

Peers: WELL VTR HCP OHI MPT HR NHI LTC SBRA XRN

| Held by: VNQ VTI VOO VB RSP VBR IVV SPY SPHD XLRE

Index	S&P 500	P/E	167.95	EPS (ttm)	0.10	Insider Own	0.41%	Shs Outstand	695.04M	Perf Week	-1.74%
Market Cap	12.09B	Forward P/E	59.39	EPS next Y	0.29	Insider Trans	0.00%	Shs Float	692.22M	Perf Month	0.12%
Enterprise Value	22.67B	PEG	1.32	EPS next Q	0.06	Inst Own	97.32%	Short Float	4.63%	Perf Quarter	2.10%
Income	70.51M	P/S	4.28	EPS this Y	138.56%	Inst Trans	0.90%	Short Ratio	3.57	Perf Half Y	-6.39%
Sales	2.82B	P/B	1.57	EPS next Y	19.85%	ROA	0.35%	Short Interest	32.08M	Perf YTD	5.60%
Book/sh	10.79	P/C	22.49	EPS next 5Y	45.02%	ROE	0.89%	52W High	20.81 -18.40%	Perf Year	-15.23%
Cash/sh	0.76	P/FCF	10.55	EPS past 3/5Y	-52.08% -	ROIC	0.42%	52W Low	15.71 8.08%	Perf 3Y	-18.98%
Dividend Est.	1.25 (7.34%)	EV/EBITDA	14.14	Sales past 3/5Y	11.05% 11.40%	Gross Margin	22.48%	Volatility	2.42% 2.66%	Perf 5Y	-44.59%
Dividend TTM	1.12 (6.61%)	EV/Sales	8.03	EPS Y/Y TTM	-70.88%	Oper. Margin	19.31%	ATR (14)	0.43	Perf 10Y	-40.83%
Dividend Ex-Date	Mar 17, 2026	Quick Ratio	1.66	Sales Y/Y TTM	4.52%	Profit Margin	2.50%	RSI (14)	44.82	Recom	2.00
Dividend Gr. 3/5Y	0.55% -3.79%	Current Ratio	1.66	EPS Q/Q	2500.00%	SMA20	-1.73%	Beta	1.08	Target Price	19.36
Payout	1204.37%	Debt/Eq	1.38	Sales Q/Q	3.07%	SMA50	-0.96%	Rel Volume	0.76	Prev Close	16.90
Employees	411	LT Debt/Eq	1.24	Earnings	Feb 02 AMC	SMA200	-3.40%	Avg Volume	9.00M	Price	16.98
IPO	Jul 19, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	128.57% 1.90%	Trades		Volume	6,898,713	Change	0.47%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-05-26	Downgrade	Argus	Buy → Hold
Jan-09-26	Initiated	Goldman	Neutral	$17
Dec-16-25	Downgrade	Jefferies	Buy → Hold	$17
Oct-01-25	Initiated	Cantor Fitzgerald	Neutral	$20
Sep-15-25	Upgrade	Raymond James	Mkt Perform → Outperform	$20
Aug-20-25	Downgrade	Deutsche Bank	Buy → Hold	$18
Jul-29-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$19
Jan-15-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$25
Oct-21-24	Upgrade	Deutsche Bank	Hold → Buy	$20 → $28
May-03-24	Upgrade	Wedbush	Neutral → Outperform
Apr-26-24	Upgrade	Exane BNP Paribas	Neutral → Outperform	$19 → $21
Apr-22-24	Resumed	Mizuho	Buy	$22
Apr-01-24	Upgrade	BofA Securities	Underperform → Buy	$18 → $25
Mar-25-24	Resumed	Wells Fargo	Equal Weight	$19
Mar-08-24	Resumed	RBC Capital Mkts	Outperform	$21
Jan-05-24	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
May-26-23	Initiated	JMP Securities	Mkt Outperform	$15.50
Apr-20-23	Initiated	Wells Fargo	Underweight	$14
Dec-14-22	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$17
Oct-28-22	Initiated	JP Morgan	Neutral	$17

Show Previous Ratings

Today 06:44AM	Healthpeak Properties and Janus Living Announce Launch of Janus Living Initial Public Offering (Business Wire)
Mar-04-26 11:30AM	Healthpeak (DOC) Up 6.3% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-03-26 02:00PM	These S&P 500 Dividend Stocks Are Quietly Crushing the Index And Paying You Monthly (24/7 Wall St.)
08:18AM	Time for Boomers to Play It Safe: Our 5 Safest Monthly Pay Dividend Stocks (24/7 Wall St.)
Feb-27-26 05:30PM	Healthpeak Properties, Inc. Announces Public Filing of Registration Statement with the SEC for Janus Living, Inc. (Business Wire)
01:19PM	Loading…
Feb-19-26 01:19PM	REITs Set for a 2026 Rebound? 7 Top Picks as Rate Cuts Approach (MarketBeat)
Feb-12-26 11:37AM	Equinix Q4 AFFO & Revenues Miss Estimates but Grow Y/Y, Dividend Hiked (Zacks)
Feb-11-26 11:49AM	Welltower's Q4 FFO & Revenues Beat Estimates, Same Store NOI Rises (Zacks)
10:17AM	Red-Hot Jobs Report Will Delay Fed Rate Cuts Lock In These 5 Ultra-High-Yield Dividend Giants (24/7 Wall St.)
Feb-06-26 11:28AM	Ventas Q4 FFO Meet, Revenues Beat Estimates, Same-Store Cash NOI Rises (Zacks)
Feb-04-26 12:48PM	2 REITs That Look Attractive in a Stable Rate Environment (MarketBeat)
Feb-03-26 10:08PM	Healthpeak Properties Q4 Earnings Call Highlights (MarketBeat)
04:48PM	Analyst Report: Healthpeak Properties, Inc. (Morningstar Research)
04:21PM	Goldman Sachs Highlights Improving Occupancy and Cash Flow Visibility at Healthpeak Properties Inc. (DOC) (Insider Monkey)
04:02PM	Healthpeak Properties Inc (DOC) Q4 2025 Earnings Call Highlights: Strategic Moves and ... (GuruFocus.com)
08:34AM	Loading…
08:34AM	Healthpeak Q4 FFO Beats Estimates, Same-Store NOI Rises Y/Y (Zacks)
04:58AM	What Are Wall Street Analysts' Target Price for Healthpeak Properties Stock? (Barchart)
Feb-02-26 05:35PM	Healthpeak (DOC) Beats Q4 FFO and Revenue Estimates (Zacks)
04:42PM	Healthpeak: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Healthpeak Properties Provides Strategic Initiatives Update and Reports Fourth Quarter 2025 Results (Business Wire)
Jan-29-26 05:25PM	Analyst Report: Healthpeak Properties, Inc. (Morningstar Research)
11:12AM	What's in the Cards for Healthpeak Properties This Earnings Season? (Zacks)
09:18AM	Boomers and Gen-X Are Grabbing 5 Passive Income High-Yield Giants Before 2026 Rate Cuts (24/7 Wall St.)
09:00AM	SL Green's Q4 FFO & Revenues Beat Estimates, Rental Rates Improve (Zacks)
Jan-28-26 08:25AM	Boston Properties' Q4 Revenues and FFO Miss Estimates (Zacks)
Jan-27-26 11:12AM	Alexandria's Q4 AFFO & Revenues Beat Estimates, Occupancy Decline Y/Y (Zacks)
Jan-22-26 09:48AM	Healthpeak Properties Stock Up 13.5% in a Month: Will the Trend Last? (Zacks)
Jan-21-26 04:15PM	Healthpeak Advances AI-Enabled Operating Platform, Naming Omkar Joshi Head of Enterprise Innovation (Business Wire)
10:56AM	Prologis Q4 FFO Meets Estimates, Rental Revenues Rise Y/Y (Zacks)
09:35AM	Should You Forget Realty Income and Buy Healthpeak Properties Instead? (Motley Fool)
11:53AM	Loading…
Jan-20-26 11:53AM	Monthly Income: A Portfolio of 2 ETFs and 2 Stocks (24/7 Wall St.)
Jan-15-26 04:15PM	Healthpeak Properties Announces Tax Treatment of 2025 Distributions (Business Wire)
Jan-14-26 10:24AM	Healthpeak Announces Transaction Activity Amounting $925 Million (Zacks)
Jan-12-26 06:59AM	Healthpeak Properties Announces $925 Million of Transaction Activity (Business Wire)
Jan-09-26 04:15PM	Healthpeak Properties Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details (Business Wire)
Jan-08-26 08:46AM	Healthpeak Monetizes Senior Housing Assets Through Janus Living IPO (Zacks)
Jan-07-26 07:01AM	Healthpeak Properties Announces the Formation of a Pure-Play, RIDEA-Structured Publicly Traded Senior Housing REIT (Business Wire)
07:00AM	Healthpeak Properties Announces Confidential Submission of Draft Registration Statement by Janus Living, Inc. (Business Wire)
Jan-05-26 04:15PM	Healthpeak Properties Declares Monthly Common Stock Cash Dividends for the First Quarter of 2026 (Business Wire)
05:42AM	What You Need To Know Ahead of Healthpeak Properties Earnings Release (Barchart)
Dec-31-25 09:40AM	Here's Why Healthpeak (DOC) is a Strong Value Stock (Zacks)
Dec-26-25 08:55AM	How to Boost Your Portfolio with Top Finance Stocks Set to Beat Earnings (Zacks)
Dec-20-25 05:35AM	6 Ultra-High-Yield Dividend Stocks for Safe Income in 2026 and Beyond (Motley Fool)
Dec-18-25 09:41AM	3 New Year's Resolution Stocks That Could Turn Around in 2026 (MarketBeat)
03:04AM	Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500? (Motley Fool)
Dec-17-25 09:41AM	More Rate Cuts Are Coming in 2026: Grab These Safe 7% and 8% Dividend Stocks Now (24/7 Wall St.)
Dec-16-25 09:09AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More (24/7 Wall St.)
Dec-15-25 05:09AM	Is Healthpeak Properties Stock Underperforming the Dow? (Barchart)
Dec-11-25 09:40AM	Why Healthpeak (DOC) is a Top Value Stock for the Long-Term (Zacks)
Dec-10-25 11:47AM	This Invesco ETF Pays a 4.71% Yield With 50 Low-Volatility Dividend Stocks (3x the S&P 500) (24/7 Wall St.)
Dec-08-25 06:00AM	Healthpeak Properties Publishes Updated Investor Presentation (Business Wire)
Dec-07-25 08:25PM	Got $2,000 to Invest in December? These Dividend Stocks Could Turn It into a Monthly Stream of Passive Income in 2026. (Motley Fool)
Dec-04-25 05:03PM	Wall Street Sees a 60% Upside to Healthpeak Properties (DOC) (Insider Monkey)
Nov-27-25 11:30AM	W.P. Carey (WPC) Up 1.7% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-26-25 11:30AM	Why Is Alexandria Real Estate Equities (ARE) Down 16.4% Since Last Earnings Report? (Zacks)
Nov-25-25 11:48AM	3 Best Monthly Paying Dividend Stocks in the S&P 500 (24/7 Wall St.)
Nov-20-25 09:57AM	Analyst Report: Healthpeak Properties, Inc. (Morningstar Research)
Nov-11-25 06:36PM	Analyst Report: Healthpeak Properties, Inc. (Morningstar Research)
Nov-05-25 01:15PM	Healthpeak Properties Stock: Is Wall Street Bullish or Bearish? (Barchart)
Nov-04-25 01:38PM	3 High-Yield Monthly Dividend Stocks That Pay You Like Clockwork (24/7 Wall St.)
Nov-03-25 07:03AM	3 Safe and Steady Stocks for Any Market (MarketBeat)
Oct-30-25 01:27PM	Ventas Q3 FFO and Revenues Beat Estimates, Same-Store Cash NOI Rises (Zacks)
01:07PM	Equinix Q3 AFFO Beats Estimates, Recurring Revenues Rise Y/Y (Zacks)
Oct-28-25 12:22PM	Welltower's Q3 FFO & Revenues Beat Estimates, Same Store NOI Rises (Zacks) -5.40%
Oct-24-25 05:02PM	Healthpeak Properties Inc (DOC) Q3 2025 Earnings Call Highlights: Strong Financial Performance ... (GuruFocus.com)
01:34PM	Healthpeak Q3 FFO Beats Estimates, Same-Store NOI Rises Y/Y (Zacks)
Oct-23-25 06:00PM	Healthpeak (DOC) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:25PM	Healthpeak (DOC) Beats Q3 FFO and Revenue Estimates (Zacks)
04:21PM	Healthpeak: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Healthpeak Properties Provides Strategic Initiatives Update and Reports Third Quarter 2025 Results (Business Wire)
Oct-21-25 11:12AM	What's in the Cards for Healthpeak Properties This Earnings Season? (Zacks)
09:15AM	Wall Street's Insights Into Key Metrics Ahead of Healthpeak (DOC) Q3 Earnings (Zacks)
Oct-16-25 03:07PM	3 Ultra-High-Yield Dividend Stocks With 7.2% Average Yields to Buy in October (Motley Fool)
Oct-15-25 09:10AM	Prologis (PLD) Tops Q3 FFO Estimates (Zacks)
Oct-07-25 02:16AM	What to Expect From Healthpeak Properties Next Quarterly Earnings Report (Barchart)
Oct-06-25 04:15PM	Healthpeak Properties Declares Monthly Common Stock Cash Dividends for the Fourth Quarter of 2025 (Business Wire)
04:51AM	2 Top Dividend Stocks to Buy With Less Than $50 (Motley Fool)
Oct-05-25 08:17AM	Investing $50,000 Into These Top Real Estate Dividend Stocks Could Produce Nearly $250 of Passive Income Each Month (Motley Fool)
Oct-03-25 06:21AM	Is AGNC Investment a Better Dividend Stock Than Healthpeak Properties? (Motley Fool)
Oct-01-25 01:00PM	Dividend Dependability: How Healthpeak Properties (DOC) Supports Long-Term Income Strategies (Insider Monkey)
Sep-28-25 06:33PM	2 No-Brainer Dividend Stocks With Yields Above 5% You Can Buy Now and Hold at Least a Decade (Motley Fool)
Sep-27-25 03:06AM	Investing $2,500 in This Basket of Dividend Stocks Should Give You Nearly $200 in Yearly Income (Motley Fool)
Sep-25-25 04:15PM	Healthpeak Properties Announces Third Quarter 2025 Earnings Release Date and Conference Call Details (Business Wire)
Sep-23-25 03:53AM	Is Healthpeak Properties Stock Underperforming the Nasdaq? (Barchart)
Sep-21-25 04:24AM	Street Calls of the Week (Investing.com)
Sep-15-25 09:40AM	Broadcom initiated, Beyond Meat downgraded: Wall Street's top analyst calls (The Fly)
08:56AM	Raymond James upgrades Healthpeak, downgrades Healthcare Realty to Underperform (Investing.com)
Sep-11-25 04:59AM	2 Undervalued Healthcare Stocks to Buy in 2025 and Hold for Decades (Motley Fool)
Sep-04-25 04:15PM	Healthpeak Properties Publishes Its 14th Annual Corporate Impact Report (Business Wire)
Sep-02-25 03:21AM	3 High-Yield Dividend Stocks You Can Buy in September and Hold Forever (Motley Fool)
Aug-27-25 06:00AM	Healthpeak Strengthens Life Science Leadership with Addition of Denis Sullivan as Managing Director of Lab Investments & San Diego Market Lead and Promotion of Mike Dorris as Head of West Coast Development & Construction (Business Wire)
Aug-23-25 03:11AM	Want Safe Dividend Income in 2025 and Beyond? Invest in the Following 5 Ultra-High-Yield Stocks. (Motley Fool)
Aug-20-25 08:13AM	2 Dirt-Cheap High-Dividend Stocks to Buy Right Now (Motley Fool)
Aug-19-25 02:04PM	Real Estate Is the S&P 500's Best Performer Today (Barrons.com)
Aug-16-25 10:28PM	Here's How You Can Earn $100 In Passive Income By Investing In Healthpeak Properties Stock (Benzinga)
Aug-15-25 10:00AM	Here's Why You Should Retain Welltower Stock in Your Portfolio Now (Zacks)
Aug-14-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Aug-13-25 01:36AM	CEO Share Purchases Contrast Analyst Downgrades for Healthpeak (Insider Monkey)
Aug-07-25 10:21AM	Healthpeak Properties Stock: Analyst Estimates & Ratings (Barchart)
Aug-06-25 04:38AM	Zacks Investment Ideas feature highlights: MSCI, Charter Communications and Healthpeak Properties (Zacks)

Healthpeak Properties, Inc. is a Standard & Poor's 500 company, which engages in acquiring, developing, owning, leasing, and managing healthcare real estate across the United States. It operates through the following segments: Lab, Outpatient Medical, Continuing Care Retirement Community (CCRC), and Other Non-Reportable. The Lab segment refers to lab properties, which contain laboratory and office space. The Outpatient Medical segment includes outpatient medical buildings and hospitals. The CCRC segment deals with retirement communities that include independent living, assisted living, memory care, and skilled nursing units. The Other Non-Reportable segment consists of an unconsolidated joint venture with a sovereign wealth fund that owns 19 senior housing assets and loans receivable. The company was founded in 1985 and is headquartered in Denver, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thomas John T	Director	Aug 06 '25	Buy	17.05	1,450	24,730	810,016	Aug 06 03:09 PM
Brinker Scott M	President and CEO	Aug 04 '25	Buy	16.83	1,490	25,077	211,906	Aug 04 11:16 AM
Brinker Scott M	President and CEO	Jul 31 '25	Buy	17.06	2,930	49,986	210,416	Jul 31 01:59 PM
Brinker Scott M	President and CEO	Jul 28 '25	Buy	17.40	2,873	49,990	207,486	Jul 29 12:02 PM
Scott Peter A	officer in 90 day cool down pe	Jul 01 '25	Proposed Sale	17.88	100,050	1,788,894		Jul 01 06:36 PM
Thompson Tommy G	Director	May 28 '25	Buy	17.27	5,777	99,769	144,290	May 28 01:15 PM
Thompson Tommy G	Director	May 09 '25	Buy	17.36	5,700	98,974	138,513	May 12 12:02 PM
Brinker Scott M	President and CEO	May 09 '25	Buy	17.39	2,750	47,822	204,613	May 12 12:01 PM
Lias-Booker Ava	Director	Apr 29 '25	Buy	17.83	5,000	89,150	35,561	Apr 29 05:06 PM
Thomas John T	Director	Apr 28 '25	Buy	17.84	4,200	74,928	813,566	Apr 28 05:56 PM
Sandstrom Katherine M	Director	Apr 28 '25	Buy	17.65	11,288	199,233	56,268	Apr 28 05:54 PM
Lewis Sara Grootwassink	Director	Apr 28 '25	Buy	17.66	6,000	105,938	9,000	Apr 28 05:52 PM
SHELLEY-KESSLER PAMELA	Director	Apr 28 '25	Buy	17.61	2,838	49,991	3,965	Apr 28 05:51 PM
Brinker Scott M	President and CEO	Apr 28 '25	Buy	17.68	11,337	200,438	201,863	Apr 28 05:49 PM

UTHR

United Therapeutics Corp

TXMD

TherapeuticsMD Inc

DOC

Healthpeak Properties Inc

Upgrade your FINVIZ experience